Drug intelligence / Profile preview

sss40

Development stage: Phase 2
Lead developer: 3SBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

SSS40 is a high-affinity humanized monoclonal antibody that directly binds to nerve growth factor (NGF), neutralizing its biological activity and blocking pain signal transmission. It works by inhibiting the NGF signaling pathway, regulating the expression of pain-related substances, and desensitizing pain neurons to inflammatory responses, thereby achieving analgesic effects. It is being developed primarily for the treatment of bone metastasis pain.

Other names: humanized nerve growth factor antibodyhumanized NGF antibody

Targets

NGF (Nerve growth factor)

Beyond the preview

Go deeper on sss40.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sss40.

Explore the full profile